BlueChew

**BlueChew** is a U.S. prescription telehealth brand operated by Dermacare that provides compounded erectile-dysfunction treatments in chewable, sublingual, and certain liquid formulations. Its core ED offerings contain the phosphodiesterase type 5 inhibitors sildenafil, tadalafil, or vardenafil; some product formulations also include apomorphine, oxytocin, and caffeine. PDE5 inhibition increases cyclic guanosine monophosphate signaling and promotes smooth-muscle relaxation and penile blood flow during sexual stimulation. BlueChew is a product-line and telemedicine-service brand rather than one chemically uniform drug, and its compounded finished products are not FDA-approved. FDA issued Dermacare dba BlueChew a warning letter dated September 9, 2025 concerning false or misleading promotional claims for compounded sildenafil and tadalafil products. ([fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dermacare-llc-dba-bluechew-716698-09092025))

Brand names

BlueChew